Results 81 to 90 of about 40,364 (272)

Multiple Therapy Approach for Stage 3 Coats Disease: Long-Term Follow-Up

open access: yesJournal of Ophthalmology, 2020
Purpose. To assess long-term efficacy of a multiple therapy approach in the treatment and management of unilateral stage 3 Coats disease with exudative retinal detachment. Methods.
Rodolfo Mastropasqua   +3 more
doaj   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

open access: yesMolecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos   +6 more
wiley   +1 more source

Coats plus in prematurity

open access: yes, 2022
Coats plus syndrome or cerebroretinal microangiopathy with calcifications and cysts (CMCC) is an exceedingly rare autosomal recessive disorder that predominantly affects the microvasculature in the retina, brain, bones, and gastrointestinal system ...
Al-Khersan, Hasenin   +6 more
core   +1 more source

Engineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang   +12 more
wiley   +1 more source

Pearls and pitfalls in diagnosis and management of coats disease

open access: yes, 2015
PURPOSE: To review current literature on Coats disease and provide a structured framework for differentiating challenging clinical features in Coats disease patients.
M. Pellegrini   +5 more
core   +1 more source

Reemergence of dormant Coats disease after 30 years.

open access: yes, 2012
Purpose. We describe an atypical case of a patient with Coats disease that re-emerged after 30 years, illustrating a previously poorly understood long-term evolution of the disease. Methods.
Pérez-Campagne, E., Wolfensberger, T.J.
core   +2 more sources

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

open access: yesMolecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni   +11 more
wiley   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

open access: yesMolecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh   +12 more
wiley   +1 more source

Coats' disease and calcification: a case report.

open access: yes, 1996
Intraocular calcification can rarely occur in Coats' disease. To our best knowledge, all previously reported cases with intraocular calcification had significant exudative detachment.
Memisoglu, B.   +4 more
core  

Bilateral Fluorescein Angiographic Findings in Unilateral Coats’ Disease

open access: yes, 2011
Two patients with clinically unilateral Coats' disease were imaged with fluorescein angiography during an examination under anesthesia. Both patients were found to have abnormal retinal vasculature in their contralateral eye. These findings may represent
Ditte J. Hess   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy